G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Globes – Israel
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform
  • This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely
  • G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment
  • Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device
  • G Medical is steady on the market and shares are currently trading for 4.2 cents each

Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform.

This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely.

G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment.

Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device.

Additionally, G Medical will receive reimbursements for the service and the price will vary depending on the length of the monitoring period.

“Providing hospital partners with the ability to monitor patients undergoing TAVR treatment through our IDTF platform is another valuable revenue channel,” CEO Dr Yacov Geva said.

“As the addressable market for telehealth grows, we are very confident IDTF will continue to scale up. We are making excellent headway in the U.S. university hospital market and our large sales team is identifying many more opportunities for growth,” he added.

G Medical is steady on the market and shares are trading for 4.2 cents each at 12:25 pm AEST.

gmv by the numbers
More From The Market Online

Argent Biopharma executes global licence for non-core Cannabis genetics

Argent BioPharma has entered into a worldwide licensing agreement with TPI for the commercial development of…

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…